Risk factors for central serous chorioretinopathy. Systematic review and meta-analysis.

Journal «MEDICINA» № 1, 2020, pp.102-124 (Reviews)

Authors

Khasanova G. R.
MD, PhD, Associate professor, Head, Department of epidemiology and evidence-based medicine¹

Hakimov N. M.
PhD, Associate professor, Department of epidemiology and evidence-based medicine¹

Аgliullin D. R.
Postgraduate student, Department of epidemiology and evidence-based medicine¹

Abdulaeva E. A.
PhD, Associate professor, Head, Department of ophthalmology²

1 - Kazan State Medical University, Kazan, Russia
2 - Kazan State Medical Academy – Branch Campus of the FSBEIFPE RMACPE MOH Russia, Kazan, Russia

Corresponding Author

Agliullin Damir; e-mail: dr.agliullin@gmail.com

Conflict of interest

None declared.

Funding

The study had no sponsorship.

Abstract

The aim of the study was to conduct a systematic review and meta-analysis of the role of the following risk factors for central serous chorioretinopathy: the use of steroid and non-steroidal anti-inflammatory drugs, psychopharmacological drugs, obstructive sleep apnea syndrome, coronary heart disease, autoimmune diseases, arterial hypertension, Helicobacter pylori infection, tobacco smoking. Methods: A literature search was conducted in English and Russian using electronic databases PubMed, Web of Science, Сochrane Library, E-library. Links from found studies were also analyzed. Selected articles were published during the period from June 1986 to June 5, 2019. The odds ratio (OR) with a confidence interval of 95% (CI) were calculated. Results: In accordance with the inclusion criteria, 25 trials were selected (21 trials – case – control studies and 4 cohort), involving 32747 patients with diagnosed central serous chorioretinopathy and 129980 people without it. According to the results of a meta-analysis, the risk factors for the disease were: the use of steroid drugs (OR 3.60; 95% CI 2.13-6.08); coronary heart disease (OR 1.39; 95% CI 1.11-1.74); the presence of an autoimmune disease (OR 2.35; 95% CI 1.09-5.05); arterial hypertension (OR 1.59; 95% CI 1.13-2.24); Helicobacter pylori infection (OR 2.45; 95% CI 1.56-3.85). The association of central serous chorioretinopathy with tobacco smoking (OR 1.43; 95% CI 0.75-2.73), obstructive sleep apnea syndrome (OR 1.82; 95% CI 0.70-4.75), and the use of non-steroidal anti-inflammatory drugs (OR 0.96; 95% CI 0.83-1.11), the use of psychopharmacological drugs (OR 1.52; 95% CI 0.91-2.53) have not been demonstrated. Conclusions: The most likely risk factors for central serous chorioretinopathy are diseases and conditions associated with the presence of endothelial dysfunction, such as arterial hypertension, ischemic hard disase, autoimmune diseases, and the use of steroid drugs.

Key words

central serous chorioretinopathy, systematic review, meta-analysis, risk factors, corticosteroids, coronary heart disease, arterial hypertension

DOI

10.29234/2308-9113-2020-8-1-102-124

References

1. Liegl R., Ulbig M.W. Central Serous Chorioretinopathy. Ophthalmologica 2014; 232: 65-76. doi: 10.1159/000360014.

2. Gass J.D.M. Pathogenesis of disciform detachment of the neuroepithelium: Idiopathic central serous choroidopathy. Am J Ophthalmology 1967; 63: 587-615.

3. Schatz H. Central serous chorioretinopathy and serous detachment of the retinal pigment epithelium. Int Ophthalmol Clin 1975; 15: 159-168.

4. Nicholson B., Noble J., Forooghian F., Meyerle C. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 2013; 58: 103-126.

5. Liew G., Quin G., Gillies M., Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Experiment Ophthalmol 2013; 41: 201-214.

6. Yap E.Y., Robertson D.M. The long-term outcome of central serous chorioretinopathy. Arch Ophthalmol 1996; 114: 689-692.

7. Ficker L., Vafidis G., While A., Leaver P. Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 1988; 72: 829-834.

8. Haimovici R., Koh S., Gagnon D.R., Lehrfeld T., Wellik S. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology 2004; 111: 244-249. doi: 10.1016/j.ophtha.2003.09.024.

9. Mateo-Montoya A., Mauget-Faÿse M. Helicobacter pylori as a risk factor for central serous chorioretinopathy: Literature review. World J Gastrointest Pathophysiol 2014; 5:355-358.

10. Yannuzzi L.A. Type A behavior and central serous chorioretinopathy. Retina 2012; 32: 709.

11. Chatziralli I., Kabanarou S.A., Parikakis E., Chatzirallis A., Xirou T., Mitropoulos P. Risk factors for central serous chorioretinopathy: multivariate approach in a case-control study. Current Eye Research 2017; 42(7): 1069-1073. doi: 10.1080/02713683.2016.1276196.

12. van Dijk E.H.C., Tsonaka R., Klar-Mohamad N., Wouters D., de Vries A.P.J., de Jong E.K., et al. Systemic complement activation in central serous chorioretinopathy. PLoS ONE 2017; 12(7). doi: 10.1371/journal.pone.0180312.

13. Tsai D.C., Chen S.J., Huang C.C. Risk of central serous chorioretinopathy in adults prescribed oral corticosteroids: a population-based study in Taiwan. Retina 2014; 34: 1867-1874. doi: 10.1097/IAE.0000000000000159.

14. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gøtzsche P.C., Ioannidis J.P., Clarke M., Devereaux P.J., Kleijnen J., Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin. Epidemiol. 2009; 62(10): 1-34. doi: 10.1016/j.jclinepi.2009.06.006.

15. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25: 603-605.

16. Tittl M.K., Spaide R.F., Wong D., Pilotto E., Yannuzzi L.A., et al. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol. 1999; 128: 63-68. doi: 10.1016/S0002-9394(99)00075-6.

17. Carvalho-Recchia C.A., Yannuzzi L.A., Negra S., et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology 2002; 109: 1834-1837.

18. Zhou H., Cai N., Liu M.Z., Cai B. Systematic factors associated with central serous chorioretinopathy. J Tradit Chin Ophthalmol. 2001; 11: 155.

19. Mansuetta C.C., Mason J.O., Swanner J., Feist R.M., White Jr. M.F., Thomley M.L., McGwin Jr G., Emond T.L. An association between central serous chorioretinopathy and gastroesophageal reflux disease. Am J Ophthalmol. 2004; 137: 1096–1100. doi: 10.1016/j.ajo.2004.01.054.

20. Karadimas P., Bouzas E.A. Glucocorticoid use represents a risk factor for central serous chorioretinopathy: a prospective, case-control study. Graefes Arch Clin Exp Ophthalmol. 2004; 242: 800-802. doi: 10.1007/s00417-004-0885-z.

21. Cotticelli L., Borrelli M., D’Alessio A.C. Menzione M, Villani A., Piccolo G., Montella F., Iovene M.R., Romano M. Central serous chorioretinopathy and Helicobacter pylori. Eur J Ophthalmol. 2006; 16(2): 274-8.

22. Leveque T.K., Yu L., Musch D.C., Chervin R.D., Zacks D.N. Central serous chorioretinopathy and risk for obstructive sleep apnea. Sleep Breath. 2007; 11: 253-7. doi: 10.1007/s11325-007-0112-3.

23. Feghhi M., Hajiani E., Khataminia G. Incidence of Helicobacter pylori in central serous chorioretinopathy a case control study. Jundishapur J Microb. 2008; 1(1): 15-9.

24. Asensio-Sanchez V.M., Rodriguez-Delgado B., Garcia-Herrero E., Cabo-Vaquera V., Garcia-Loygorri C. Central serous chorioretinopathy as an extradigestive manifestation of Helicobacter pylori gastric infection. Arch Soc Esp Oftalmol. 2008; 83(3): 177-82.

25. Misiuk-Hojlo M., Michalowska M., Turno-Krecicka A. Helicobacter pylori – a risk factor for the development of the central serous chorioretinopathy. Klin Oczna 2009; 111(1-3): 30-2.

26. Eom Y.S., Oh J., Kim S.W., Huh K. Systemic factors associated with central serous chorioretinopathy in Koreans. Korean J Ophthalmol. 2012; 26: 260-264.

27. Roshani M., Ahangar Davoodi N., Seyed Majidi M.R. et al. Association of Helicobacter pylori with central serous chorioretinopathy in Iranian patients. Gastroenterol Hepatol Bed Bench 2014; 7: 63-67.

28. Chen S.N., Lian I., Chen Y.C., Ho J.D. Increased incidence of peptic ulcer disease in central serous chorioretinopathy patients: a population-based retrospective cohort study. Retina 2015; 35: 231-237. doi: 10.1097/IAE.0000000000000278.

29. Brodie F.L., Charlson E.S., Aleman T.S. et al. Obstructive sleep apnea and central serous chorioretinopathy. Retina 2015; 35: 238-243.

30. Chang Y.-S., Weng S.-F., Chang C., Wang J.-J., Wang J.-Y., Jan R.-L. Associations between topical ophthalmic corticosteroids and central serous chorioretinopathy: a Taiwanese population-based study. Invest Ophthalmol Vis Sci. 2015; 56: 4083-4089. doi: 10.1167/iovs.14-16360.

31. Lahousen T., Painold A., Luxenberger W., Schienle A., Kapfhammer H.P., Ille R. Psychological factors associated with acute and chronic central serous chorioretinopathy. Nord J Psychiatry 2016; 70(1): 24-30. doi: 10.3109/08039488.2015.1041156.

32. Bousquet E., Dhundass M., Lehmann M., Rothschild P.-R., Bayon V., Leger D., Bergin C., Dirani A., Beydoun T., Behar-Cohen F. Shift work: a risk factor for central serous chorioretinopathy. American Journal of Ophthalmology 2016. doi: 10.1016/j.ajo.2016.02.012.

33. Manayath G.J., Arora S., Parikh H., Shah P.K., Tiwari S., Narendran V. Is myopia a protective factor against central serous chorioretinopathy? Int J Ophtalmol. 2016; 9(2): 266-270. doi: 10.18240/ijo.2016.02.16

34. Mansour A.M., Koaik M., Lima L.H., Casella A.M.B., Uwaydat S.H., Shahin M. et al. Physiologic and Psychologic Risk Factors in Central Serous Chorioretinopathy. Ophthalmol Retina 2017; 1(6): 497-507. doi: 10.1016/j.oret.2017.02.009.

35. Ersoz M.G., Arf S., Hocaoglu M. et al. Br J Ophthalmol. 2018; 0: 1-5. doi: 10.1136/bjophthalmol-2018-312431.

36. Chen Y.-Y., Huang L.-Y., Liao W.-L., Chou P. Association between Central Serous Chorioretinopathy and Risk of Depression: A Population-Based Cohort Study. Hindawi Journal of Ophthalmology 2019. doi: 10.1155/2019/2749296.

37. Tsai D.C., Chen S.J., Huang C.C. Epidemiology of idiopathic central serous chorioretinopathy in Taiwan, 2001–2006: a population-based study. PLoS One 2013. doi: 10.1371/journal.pone.0066858.

38. Bouzas E.A., Karadimas P., Pournaras C.J. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol 2002; 47: 431-448.

39. Grover D.P. Obstructive sleep apnea and ocular disorders. Curr Opin Ophthalmol 2010; 21: 454-458.

40. Henley D.E., Russell G.M., Douthwaite J.A. et al. Hypothalamicpituiary-adrenal axis activation in obstructive sleep apnea: the effect of continuous positive airway pressure therapy. J Clin Endocrinol Metab 2009; 94: 4234-4242.

41. Jain A.K., Kaines A., Schwartz S. Bilateral central serous chorioretinopathy resolving rapidly with treatment for obstructive sleep apnea. Graefes Arch Clin Exp Ophthalmol 2010; 248: 1037-1039.

42. Mauget-Faysse M., Kodjikian L., Quaranta M., Ben Ezra D., Trepsat C., Mion F. et al. Helicobacter pylori in central serous chorioretinopathy and diffuse retinal epitheliopathy. Results of the first prospective pilot study. J Fr Ophtalmol. 2002; 25(10): 1021-5.

43. Ahnoux-Zabsonre A., Quaranta M., Mauget-Faysse M. Prevalence of Helicobacter pylori in central serous chorioretinopathy and diffuse retinal epitheliopathy: a complementary study. J Fr Ophtalmol. 2004; 27(10): 1129-33. doi: MDOI-JFO-12-2004-27-10-0181-5512-101019-ART06.

44. Kmera-Muszynska M., Wojcicka I., Muszynski J. Is Helicohacter pylori infection associated with CRS occurrence? Klin Oczna 2008; 110(7-9): 273-6.

45. Warrow D., Mukkamala K., Rosen R.B. Relationship between Helicobacter Pylori and Central Serous Chorioretinopathy. Invest Ophthalmol Vis Sci. 2012; 53(14): 5227-7.

46. Franceschi F., Sepulveda A.R., Gasbarrini A., Pola P., Silveri N.G., Gasbarrini G. et al. Cross-reactivity of anti-CagA antibodies with vascular wall antigens: possible pathogenic link between Helicobacter pylori infection and atherosclerosis. Circulation 2002; 106(4): 430-4.

47. Wennmalm A. Effect of cigarette smoking on basal and carbon dioxide stimulated cerebral blood flow in man. Clin Physiol 1982; 2: 529-535.

48. Ball K., Turner R. Smoking and the heart: the basis for action. Lancet 1974; 7884: 822-826.

49. Robinson F., Petrig B.L., Riva C.E. The acute effect of cigarette smoking on macular capillary blood flow in humans. Invest Ophthalmol Vis Sci 1985; 26: 609-613.

50. Hara K. Effect of cigarette smoking on ocular circulation. Immediate effect on retinal circulation. Folia Ophthalmol Jpn 1991;42: 263-267.

51. Morgado P.B., Chen H.C., Patel V. et al. The acute effect of smoking on retinal blood flow in subjects with and without diabetes. Ophthalmology 1994; 101: 1220-1226.

52. Steigerwalt Jr R.D., Laurora G., Incandela L. et al. Ocular and orbital blood flow in cigarette smokers. Retina 2000; 20: 394-397.

53. Spaide R.F., Campeas L., Haas A. et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology 1996; 103: 2070-2079.

54. Chalon S., Moreno Jr H., Benowitz N.L. et al. Nicotine impairs endothelium-dependent dilatation in human veins in vivo. Clin Pharmacol Ther 2000; 67: 391-397.

55. Gerzanich V., Zhang F., West G.A., Simard J.M. Chronic nicotine alters NO signaling of Ca2+ channels in cerebral arterioles. Circ Res 2001; 88: 359-365.